



Altan Pharma Announces the Launch of Linezolid 2mg/ml Solution for Infusion in Spain

Dublin and Madrid, 03 March 2016: Altan Pharma Limited (“Altan”), an Irish specialty pharmaceutical company today announced that it has launched linezolid 2mg/ml solution for infusion for the treatment of community acquired pneumonia and nosocomial pneumonia in Spain through its Spanish subsidiary Genéricos Españoles Laboratorio, S.A.U.

According to IMS, the market for Linezolid solution for infusion in Spain was roughly €23 million in 2015.

About Linezolid Solution for Infusion

Linezolid is indicated for the treatment of community acquired pneumonia and nosocomial pneumonia when known or suspected to be caused by susceptible gram positive bacteria. It is also indicated for the treatment of complicated skin and soft tissue infections only when microbiological testing has established that the infection is known to be caused by susceptible Gram positive bacteria. Linezolid should only be initiated in a hospital setting.

Please see the package insert for indications, complete side effect profile and prescribing information.

About Altan Pharma Ltd.

Altan Pharma Ltd. is a privately held, specialty pharmaceutical company that develops, manufactures and commercialises injectable drugs for the hospital and other provider segments. Altan has an international distribution network covering many European, Latin American and Asian markets. The company is highly focused on building its pipeline of injectable drugs and expanding its commercial presence to new markets through both organic and inorganic means.

For more information visit www.altanpharma.com

Altan Media Relations

Tel: +353 (1) 908 1280

Email: info@altanpharma.com